In vivo effect of statins on the expression of the HIV co-receptors CCR5 and CXCR4

AIDS Research and Therapy

Edwin A Higuita¹  Fabián A Jaimes²  Maria T Rugeles¹  Carlos J Montoya¹ 

[1] Immunovirology Group, School of Medicine, University of Antioquia, Medellin, Colombia

[2] Clinical Research Unit, Hospital Pablo Tobón Uribe, Medellin, Colombia

关键词: Chemokines;    Viral tropism;    CXCR4;    CCR5;    Statins;    HIV infection;   

Others  :  789600
DOI  :  10.1186/1742-6405-10-10

 received in 2012-08-31, accepted in 2013-04-06,  发布年份 2013

【 摘 要 】

Background

During the HIV-1 replication cycle, several molecules including chemokine receptors and cholesterol are crucial, and are therefore potential targets for therapeutic intervention. Indeed statins, compounds that inhibit cellular synthesis of cholesterol and have anti-inflammatory and immunomodulatory properties were shown to inhibit HIV-1 infection by R5 tropic strains but not by X4 strains in vitro, mainly by altering the chemokine receptor/ligands axes. Therefore, the objective of this study was to characterize in vivo, the capacity of statins to modulate in HIV seronegative and chronically HIV-1-infected adults the expression of CCR5 and CXCR4, of their ligands and the tropism of circulating HIV-1 strains.

Methods

Samples from asymptomatic HIV-1-infected adults enrolled in a clinical trial aimed at evaluating the antiretroviral activity of lovastatin were used to evaluate in vivo the modulation by lovastatin of CCR5, CXCR4, their ligands, and the shift in plasma viral tropism over one year of intervention. In addition, ten HIV negative adults received a daily oral dose of 40 mg of lovastatin or 20 mg of atorvastatin; seven other HIV negative individuals who received no treatment were followed as controls. The frequency and phenotype of immune cells were determined by flow-cytometry; mRNA levels of chemokine receptors and their ligands were determined by real-time PCR. Viral tropism was determined by PCR and sequencing, applying the clonal and clinical model of analyses.

Results

Our study shows that long-term administration of lovastatin in HIV-infected individuals does not induce a shift in viral tropism, or induce a significant modulation of CCR5 and CXCR4 on immune cells in HIV-infected patients. Similar results were found in HIV seronegative control subjects, treated with lovastatin or atorvastatin, but a significant increase in CCL3 and CCL4 transcription was observed in these individuals.

Conclusions

These findings suggest that long-term administration of statins at therapeutic doses, does not significantly affect the expression of HIV-1 co-receptors or of their ligands. In addition it is important to point out that based on the results obtained, therapeutic administration of statins in HIV-infected patients with lipid disorders is safe in terms of selecting X4 strains.

【 授权许可】

   
2013 Higuita et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Simpson KN, Roberts G, Hicks CB, Finnern HW: Cost-effectiveness of tipranavir in treatment-experienced HIV patients in the United States. HIV Clin Trials 2008, 9:225-237.
• [2]Calza L: Renal toxicity associated with antiretroviral therapy. HIV Clin Trials 2012, 13:189-211.
• [3]Jones M, Nunez M: Liver toxicity of antiretroviral drugs. Semin Liver Dis 2012, 32:167-176.
• [4]Campbell JD, Stinson MJ, Simons FE, Rector ES, HayGlass KT: In vivo stability of human chemokine and chemokine receptor expression. Hum Immunol 2001, 62:668-678.
• [5]Lee B, Doranz BJ, Ratajczak MZ, Doms RW: An intricate web: chemokine receptors, HIV-1 and hematopoiesis. Stem Cells 1998, 16:79-88.
• [6]Boesecke C, Pett SL: Clinical studies with chemokine receptor-5 (CCR5)-inhibitors. Curr Opin HIV AIDS 2012, 7:456-462.
• [7]Murakami T, Yamamoto N: Role of CXCR4 in HIV infection and its potential as a therapeutic target. Future Microbiol 2010, 5:1025-1039.
• [8]Steen A, Schwartz TW, Rosenkilde MM: Targeting CXCR4 in HIV cell-entry inhibition. Mini Rev Med Chem 2009, 9:1605-1621.
• [9]Gulick RM, Lalezari J, Goodrich J, Clumeck N, DeJesus E, Horban A, Nadler J, Clotet B, Karlsson A, Wohlfeiler M: Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med 2008, 359:1429-1441.
• [10]Wasmuth JC, Rockstroh JK, Hardy WD: Drug safety evaluation of maraviroc for the treatment of HIV infection. Expert Opin Drug Saf 2012, 11:161-174.
• [11]Graham DR, Chertova E, Hilburn JM, Arthur LO, Hildreth JE: Cholesterol depletion of human immunodeficiency virus type 1 and simian immunodeficiency virus with beta-cyclodextrin inactivates and permeabilizes the virions: evidence for virion-associated lipid rafts. J Virol 2003, 77:8237-8248.
• [12]Liao Z, Cimakasky LM, Hampton R, Nguyen DH, Hildreth JE: Lipid rafts and HIV pathogenesis: host membrane cholesterol is required for infection by HIV type 1. AIDS Res Hum Retroviruses 2001, 17:1009-1019.
• [13]Liao Z, Graham DR, Hildreth JE: Lipid rafts and HIV pathogenesis: virion-associated cholesterol is required for fusion and infection of susceptible cells. AIDS Res Hum Retroviruses 2003, 19:675-687.
• [14]Manes S, del Real G, Lacalle RA, Lucas P, Gomez-Mouton C, Sanchez-Palomino S, Delgado R, Alcami J, Mira E, Martinez AC: Membrane raft microdomains mediate lateral assemblies required for HIV-1 infection. EMBO Rep 2000, 1:190-196.
• [15]Nguyen DH, Hildreth JE: Evidence for budding of human immunodeficiency virus type 1 selectively from glycolipid-enriched membrane lipid rafts. J Virol 2000, 74:3264-3272.
• [16]Nguyen DH, Taub D: CXCR4 function requires membrane cholesterol: implications for HIV infection. J Immunol 2002, 168:4121-4126.
• [17]Alkhatib G: The biology of CCR5 and CXCR4. Curr Opin HIV AIDS 2009, 4:96-103.
• [18]Kamiyama H, Yoshii H, Tanaka Y, Sato H, Yamamoto N, Kubo Y: Raft localization of CXCR4 is primarily required for X4-tropic human immunodeficiency virus type 1 infection. Virology 2009, 386:23-31.
• [19]Lodowski DT, Palczewski K: Chemokine receptors and other G protein-coupled receptors. Curr Opin HIV AIDS 2009, 4:88-95.
• [20]Saez-Cirion A, Nir S, Lorizate M, Agirre A, Cruz A, Perez-Gil J, Nieva JL: Sphingomyelin and cholesterol promote HIV-1 gp41 pretransmembrane sequence surface aggregation and membrane restructuring. J Biol Chem 2002, 277:21776-21785.
• [21]Vincent N, Genin C, Malvoisin E: Identification of a conserved domain of the HIV-1 transmembrane protein gp41 which interacts with cholesteryl groups. Biochim Biophys Acta 2002, 1567:157-164.
• [22]del Real G, Jimenez-Baranda S, Mira E, Lacalle RA, Lucas P, Gomez-Mouton C, Alegret M, Pena JM, Rodriguez-Zapata M, Alvarez-Mon M: Statins inhibit HIV-1 infection by down-regulating Rho activity. J Exp Med 2004, 200:541-547.
• [23]Greenwood J, Steinman L, Zamvil SS: Statin therapy and autoimmune disease: from protein prenylation to immunomodulation. Nat Rev Immunol 2006, 6:358-370.
• [24]Tobert JA: Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors. Nat Rev Drug Discov 2003, 2:517-526.
• [25]Nabatov AA, Pollakis G, Linnemann T, Paxton WA, de Baar MP: Statins disrupt CCR5 and RANTES expression levels in CD4(+) T lymphocytes in vitro and preferentially decrease infection of R5 versus X4 HIV-1. PLoS One 2007, 2:e470.
• [26]Bottaro EG, Caravello O, Scapellato PG, Stambulian M, Vidal GI, Loggia V, Scapellato JL, Thompson F, Cassetti I: Rosuvastatin for the treatment of dyslipidemia in HIV-infected patients receiving highly active antiretroviral therapy. Preliminary experience. Enferm Infecc Microbiol Clin 2008, 26:325-329.
• [27]De Wit S, Delforge M, Necsoi CV, Clumeck N: Downregulation of CD38 activation markers by atorvastatin in HIV patients with undetectable viral load. AIDS 2011, 25:1332-1333.
• [28]Issat T, Nowis D, Jakobisiak M, Golab J: Lovastatin potentiates antitumor effects of saquinavir against human lymphoma cells. Oncol Rep 2004, 12:1371-1375.
• [29]Maganti RM, Reveille JD, Williams FM: Therapy insight: the changing spectrum of rheumatic disease in HIV infection. Nat Clin Pract Rheumatol 2008, 4:428-438.
• [30]Visnegarwala F, Maldonado M, Sajja P, Minihan JL, Rodriguez-Barradas MC, Ong O, Lahart CJ, Hasan MQ, Balasubramanyam A, White AC Jr: Lipid lowering effects of statins and fibrates in the management of HIV dyslipidemias associated with antiretroviral therapy in HIV clinical practice. J Infect 2004, 49:283-290.
• [31]Blaak H, van’t Wout AB, Brouwer M, Hooibrink B, Hovenkamp E, Schuitemaker H: In vivo HIV-1 infection of CD45RA(+)CD4(+) T cells is established primarily by syncytium-inducing variants and correlates with the rate of CD4(+) T cell decline. Proc Natl Acad Sci U S A 2000, 97:1269-1274.
• [32]Picchio GR, Gulizia RJ, Wehrly K, Chesebro B, Mosier DE: The cell tropism of human immunodeficiency virus type 1 determines the kinetics of plasma viremia in SCID mice reconstituted with human peripheral blood leukocytes. J Virol 1998, 72:2002-2009.
• [33]Rudensey LM, Kimata JT, Benveniste RE, Overbaugh J: Progression to AIDS in macaques is associated with changes in the replication, tropism, and cytopathic properties of the simian immunodeficiency virus variant population. Virology 1995, 207:528-542.
• [34]Montoya CJ, Higuita EA, Estrada S, Gutierrez FJ, Amariles P, Giraldo NA, Jimenez MM, Velasquez CP, Leon AL, Rugeles MT, Jaimes FA: Randomized clinical trial of lovastatin in HIV-infected, HAART naive patients (NCT00721305). J Infect 2012, 65:549-558.
• [35]Montoya CJ, Jaimes F, Higuita EA, Convers-Paez S, Estrada S, Gutierrez F, Amariles P, Giraldo N, Penaloza C, Rugeles MT: Antiretroviral effect of lovastatin on HIV-1-infected individuals without highly active antiretroviral therapy (The LIVE study): a phase-II randomized clinical trial. Trials 2009, 10:41. BioMed Central Full Text
• [36]Verhofstede C, Brudney D, Reynaerts J, Vaira D, Fransen K, De Bel A, Seguin-Devaux C, De Wit S, Vandekerckhove L, Geretti AM: Concordance between HIV-1 genotypic coreceptor tropism predictions based on plasma RNA and proviral DNA. HIV Med 2011, 12:544-552.
• [37]Cardona-Maya W, Velilla P, Montoya CJ, Cadavid A, Rugeles MT: Presence of HIV-1 DNA in spermatozoa from HIV-positive patients: changes in the semen parameters. Curr HIV Res 2009, 7:418-424.
• [38]Lengauer T, Sander O, Sierra S, Thielen A, Kaiser R: Bioinformatics prediction of HIV coreceptor usage. Nat Biotechnol 2007, 25:1407-1410.
• [39]Brinkkoetter PT, Gottmann U, Schulte J, van der Woude FJ, Braun C, Yard BA: Atorvastatin interferes with activation of human CD4(+) T cells via inhibition of small guanosine triphosphatase (GTPase) activity and caspase-independent apoptosis. Clin Exp Immunol 2006, 146:524-532.
• [40]Dunn SE, Youssef S, Goldstein MJ, Prod’homme T, Weber MS, Zamvil SS, Steinman L: Isoprenoids determine Th1/Th2 fate in pathogenic T cells, providing a mechanism of modulation of autoimmunity by atorvastatin. J Exp Med 2006, 203:401-412.
• [41]Kwak B, Mulhaupt F, Veillard N, Pelli G, Mach F: The HMG-CoA reductase inhibitor simvastatin inhibits IFN-gamma induced MHC class II expression in human vascular endothelial cells. Swiss Med Wkly 2001, 131:41-46.
• [42]Oka M, Fagan KA, Jones PL, McMurtry IF: Therapeutic potential of RhoA/Rho kinase inhibitors in pulmonary hypertension. Br J Pharmacol 2008, 155:444-454.
• [43]Overmeyer JH, Maltese WA: Isoprenoid requirement for intracellular transport and processing of murine leukemia virus envelope protein. J Biol Chem 1992, 267:22686-22692.
• [44]Serhan CN, Chiang N, Van Dyke TE: Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat Rev Immunol 2008, 8:349-361.
• [45]Waiczies S, Prozorovski T, Infante-Duarte C, Hahner A, Aktas O, Ullrich O, Zipp F: Atorvastatin induces T cell anergy via phosphorylation of ERK1. J Immunol 2005, 174:5630-5635.
• [46]Weber C, Erl W, Weber KS, Weber PC: HMG-CoA reductase inhibitors decrease CD11b expression and CD11b-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolemia. J Am Coll Cardiol 1997, 30:1212-1217.
• [47]Berkowitz RD, Beckerman KP, Schall TJ, McCune JM: CXCR4 and CCR5 expression delineates targets for HIV-1 disruption of T cell differentiation. J Immunol 1998, 161:3702-3710.
• [48]Camargo JF, Quinones MP, Mummidi S, Srinivas S, Gaitan AA, Begum K, Jimenez F, VanCompernolle S, Unutmaz D, Ahuja SS, Ahuja SK: CCR5 expression levels influence NFAT translocation, IL-2 production, and subsequent signaling events during T lymphocyte activation. J Immunol 2009, 182:171-182.
• [49]Soares R, Foxall R, Albuquerque A, Cortesao C, Garcia M, Victorino RM, Sousa AE: Increased frequency of circulating CCR5+ CD4+ T cells in human immunodeficiency virus type 2 infection. J Virol 2006, 80:12425-12429.
• [50]Stoddart CA, Keir ME, McCune JM: IFN-alpha-induced upregulation of CCR5 leads to expanded HIV tropism in vivo. PLoS Pathog 2010, 6:e1000766.
• [51]Paxton WA, Liu R, Kang S, Wu L, Gingeras TR, Landau NR, Mackay CR, Koup RA: Reduced HIV-1 infectability of CD4+ lymphocytes from exposed-uninfected individuals: association with low expression of CCR5 and high production of beta-chemokines. Virology 1998, 244:66-73.
• [52]Juno JA, Fowke KR: Clarifying the role of G protein signaling in HIV infection: new approaches to an old question. AIDS Rev 2010, 12:164-176.
• [53]Ketas TJ, Kuhmann SE, Palmer A, Zurita J, He W, Ahuja SK, Klasse PJ, Moore JP: Cell surface expression of CCR5 and other host factors influence the inhibition of HIV-1 infection of human lymphocytes by CCR5 ligands. Virology 2007, 364:281-290.
• [54]Dean M, Carrington M, Winkler C, Huttley GA, Smith MW, Allikmets R, Goedert JJ, Buchbinder SP, Vittinghoff E, Gomperts E: Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia growth and development study, multicenter AIDS cohort study, multicenter hemophilia cohort study, San Francisco city cohort, ALIVE study. Science 1996, 273:1856-1862.
• [55]Huang Y, Paxton WA, Wolinsky SM, Neumann AU, Zhang L, He T, Kang S, Ceradini D, Jin Z, Yazdanbakhsh K: The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat Med 1996, 2:1240-1243.
• [56]Samson M, Libert F, Doranz BJ, Rucker J, Liesnard C, Farber CM, Saragosti S, Lapoumeroulie C, Cognaux J, Forceille C: Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 1996, 382:722-725.
• [57]Zimmerman PA, Buckler-White A, Alkhatib G, Spalding T, Kubofcik J, Combadiere C, Weissman D, Cohen O, Rubbert A, Lam G: Inherited resistance to HIV-1 conferred by an inactivating mutation in CC chemokine receptor 5: studies in populations with contrasting clinical phenotypes, defined racial background, and quantified risk. Mol Med 1997, 3:23-36.
• [58]Biti R, Ffrench R, Young J, Bennetts B, Stewart G, Liang T: HIV-1 infection in an individual homozygous for the CCR5 deletion allele. Nat Med 1997, 3:252-253.
• [59]Theodorou I, Meyer L, Magierowska M, Katlama C, Rouzioux C: HIV-1 infection in an individual homozygous for CCR5 delta 32. Seroco study group. Lancet 1997, 349:1219-1220.
• [60]Dubrovska A, Elliott J, Salamone RJ, Telegeev GD, Stakhovsky AE, Schepotin IB, Yan F, Wang Y, Bouchez LC, Kularatne SA: CXCR4 expression in prostate cancer progenitor cells. PLoS One 2012, 7:e31226.
• [61]Dubrovska A, Hartung A, Bouchez LC, Walker JR, Reddy VA, Cho CY, Schultz PG: CXCR4 activation maintains a stem cell population in tamoxifen-resistant breast cancer cells through AhR signalling. Br J Cancer 2012, 107:43-52.
• [62]Hiller D, Chu QD: CXCR4 and axillary lymph nodes: review of a potential biomarker for breast cancer metastasis. Int J Breast Cancer 2011, 2011:420981.
• [63]Kahan BD, Rutzky L, Berlin B, Tomita J, Wiseman F, LeGrue S, Noll H, Tom BH: Cell surface alterations on colon adenocarcinoma cells. Cancer Res 1976, 36:3526-3534.
• [64]Sun X, Cheng G, Hao M, Zheng J, Zhou X, Zhang J, Taichman RS, Pienta KJ, Wang J: CXCL12/CXCR4/CXCR7 chemokine axis and cancer progression. Cancer Metastasis Rev 2010, 29:709-722.
• [65]Mani D, Haigentz M Jr, Aboulafia DM: Lung cancer in HIV Infection. Clin Lung Cancer 2012, 13:6-13.
• [66]Newsom-Davis T, Bower M: HIV-associated anal cancer. F1000 Med Rep 2010, 2:85.
• [67]Shiels MS, Pfeiffer RM, Gail MH, Hall HI, Li J, Chaturvedi AK, Bhatia K, Uldrick TS, Yarchoan R, Goedert JJ, Engels EA: Cancer burden in the HIV-infected population in the United States. J Natl Cancer Inst 2011, 103:753-762.
• [68]Strehl JD, Mehlhorn G, Koch MC, Harrer EG, Harrer T, Beckmann MW, Agaimy A: HIV-associated hypertrophic herpes simplex genitalis with concomitant early invasive squamous cell carcinoma mimicking advanced genital cancer: case report and literature review. Int J Gynecol Pathol 2012, 31:286-293.
• [69]White HL, Mulambia C, Sinkala M, Mwanahamuntu MH, Parham GP, Moneyham L, Grimley DM, Chamot E: ‘Worse than HIV’ or ‘not as serious as other diseases’? Conceptualization of cervical cancer among newly screened women in Zambia. Soc Sci Med 2012, 74:1486-1493.
• [70]Yannam GR, Gutti T, Poluektova LY: IL-23 in infections, inflammation, autoimmunity and cancer: possible role in HIV-1 and AIDS. J Neuroimmune Pharmacol 2012, 7:95-112.
• [71]Zanet E, Berretta M, Di Benedetto F, Talamini R, Ballarin R, Nunnari G, Berretta S, Ridolfo A, Lleshi A, Zanghi A: Pancreatic cancer in HIV-positive patients: a clinical case–control study. Pancreas 2012, 41:1331-1335.
• [72]Colobran R, Pedrosa E, Carretero-Iglesia L, Juan M: Copy number variation in chemokine superfamily: the complex scene of CCL3L-CCL4L genes in health and disease. Clin Exp Immunol 2010, 162:41-52.